阿伐曲泊帕治疗对艾曲泊帕或海曲泊帕不耐受或无效的免疫性血小板减少症的真实世界证据
该研究纳入三个医疗中心的121例接受阿伐曲泊帕治疗的成人免疫性血小板减少症患者,按选用原因分为艾曲泊帕/海曲泊帕不耐受组和不响应组。全部患者中83%获得血小板反应(≥30×10^9/L),62%达到完全反应(≥100×10^9/L);不耐受组和不响应组分别有62%和56%的患者能够停用超过一种伴随的免疫性血小板减少症药物。
要点
- 阿伐曲泊帕治疗后83%患者血小板反应(≥30×10^9/L),62%达完全反应(≥100×10^9/L)。
- 不耐受组62%、不响应组56%的患者能停用超过一种伴随的免疫性血小板减少症药物。
- 17例多次转换血小板生成素受体激动剂的患者血小板反应率为88%。
核心结论
- 在免疫性血小板减少症人群中,阿伐曲泊帕被证明有效且安全,尤其对艾曲泊帕/海曲泊帕不耐受或不响应的患者。
- 患者从血小板生成素受体激动剂转换中获益,尤其是多次转换者。
- 然而,许多患者面临阿伐曲泊帕长期经济负担的困扰。
研究设计与样本
- 该研究为三个医疗中心开展的真实世界研究,纳入121例接受阿伐曲泊帕治疗的成人免疫性血小板减少症患者。
- 根据选用阿伐曲泊帕的原因,患者被分为艾曲泊帕/海曲泊帕不耐受组和不响应组。
主要发现
- 与不响应组相比,不耐受组中更多患者有肝病史且接受阿伐曲泊帕前的治疗更少。
- 全部患者中83%获得血小板反应(≥30×10^9/L),62%达到完全反应(≥100×10^9/L)。
- 不耐受组62%和不响应组56%的患者能够停用超过一种伴随的免疫性血小板减少症药物。
- 17例多次转换血小板生成素受体激动剂的患者血小板反应率为88%。
- 63例停用阿伐曲泊帕,其中27%因无法负担费用。
关键数值与推荐
- 血小板反应定义为血小板计数≥30×10^9/L,完全反应定义为血小板计数≥100×10^9/L。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Due to the limited real-world research on the application of avatrombopag (AVA) for immune thrombocytopenia (ITP) in China, we evaluated the effectiveness and safety of AVA in clinical practice. We included 121 adult ITP patients treated with AVA across three medical centres. Based on the reasons for choosing AVA, these patients were divided into eltrombopag (ELT)/hetrombopag (HET) intolerance group (IG), and ELT/HET unresponsive group (UG). Compared with UG, more patients in IG had a history of liver disease and received fewer treatments before AVA. Amongst all patients, 83% had platelet response (≥30 × 109/L) after AVA and 62% achieved complete response (≥100 × 109/L, CR). Sixty-two percent in IG and 56% in UG were able to discontinue more than one concomitant ITP medication. A total of 17 patients underwent multiple switches of thrombopoietin receptor agonists (TPO-RAs), resulting in an 88% platelet response rate. Sixty-three patients discontinued AVA, 27% were due to unaffordability. AVA was well tolerated in most patients. In the ITP population, AVA proved effective and safe, particularly in patients intolerant or unresponsive to ELT/HET. Patients benefited from TPO-RAs switches, particularly those undergoing multiple switches. However, many patients struggled with the long-term financial burden of AVA.
引用
- Tian H, Zhou L, Dai JW, et al. Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag. Br J Haematol. 2024. PMID: 39367620. doi:10.1111/bjh.19800
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。